374 related articles for article (PubMed ID: 29409743)
21. Chimerism and tolerance induction in kidney transplantation.
Traitanon O; Gallon L
Nephron; 2015; 129(1):34-8. PubMed ID: 25531026
[TBL] [Abstract][Full Text] [Related]
22. Successful Induction of Specific Immunological Tolerance by Combined Kidney and Hematopoietic Stem Cell Transplantation in HLA-Identical Siblings.
Fehr T; Hübel K; de Rougemont O; Abela I; Gaspert A; Güngör T; Hauri M; Helmchen B; Linsenmeier C; Müller T; Nilsson J; Riesterer O; Scandling JD; Schanz U; Cippà PE
Front Immunol; 2022; 13():796456. PubMed ID: 35173720
[TBL] [Abstract][Full Text] [Related]
23. Induction of tolerance in organ recipients by hematopoietic stem cell transplantation.
Ophir E; Reisner Y
Int Immunopharmacol; 2009 Jun; 9(6):694-700. PubMed ID: 19150657
[TBL] [Abstract][Full Text] [Related]
24. [Transplant tolerance through mixed chimerism].
Zuber J
Nephrol Ther; 2017 Apr; 13 Suppl 1():S127-S130. PubMed ID: 28577733
[TBL] [Abstract][Full Text] [Related]
25. Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism.
Gibbons C; Sykes M
Immunol Rev; 2008 Jun; 223():334-60. PubMed ID: 18613846
[TBL] [Abstract][Full Text] [Related]
26. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
27. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
Donckier V; Troisi R; Toungouz M; Colle I; Van Vlierberghe H; Jacquy C; Martiat P; Stordeur P; Zhou L; Boon N; Lambermont M; Schandené L; Van Laethem JL; Noens L; Gelin M; de Hemptinne B; Goldman M
Transpl Immunol; 2004; 13(2):139-46. PubMed ID: 15380544
[TBL] [Abstract][Full Text] [Related]
28. Adoptive immunotherapy against kidney targets in dog-leukocyte antigen-identical mixed hematopoietic canine chimeras.
Junghanss C; Takatu A; Little MT; Maciej Zaucha J; Zellmer E; Yunusov M; Sale G; Georges GE; Storb R
Transplantation; 2003 Feb; 75(3):268-74. PubMed ID: 12589144
[TBL] [Abstract][Full Text] [Related]
29. Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versus-host disease after non T cell-depleted HLA-mismatched peripheral blood stem cell transplantation.
Wu BY; Guo KY; Song CY; Yang ; Li D
Bone Marrow Transplant; 2000 Sep; 26(6):691-3. PubMed ID: 11035376
[TBL] [Abstract][Full Text] [Related]
30. The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.
Or-Geva N; Reisner Y
Bone Marrow Transplant; 2015 Jun; 50 Suppl 2():S14-20. PubMed ID: 26039201
[TBL] [Abstract][Full Text] [Related]
31. Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach.
Sasaki H; Oura T; Spitzer TR; Chen YB; Madsen JC; Allan J; Sachs DH; Cosimi AB; Kawai T
Hum Immunol; 2018 May; 79(5):258-265. PubMed ID: 29175110
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous blockade of costimulatory signals CD28-CD80 and CD40-CD154 combined with monoclonal antibody against CD25 induced a stable chimerism and tolerance without graft-versus-host disease in rat.
Zhu ZX; Fan LY; Wang Q
Eur Surg Res; 2011; 46(3):109-17. PubMed ID: 21242693
[TBL] [Abstract][Full Text] [Related]
33. Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning.
Seung E; Mordes JP; Rossini AA; Greiner DL
J Clin Invest; 2003 Sep; 112(5):795-808. PubMed ID: 12952928
[TBL] [Abstract][Full Text] [Related]
34. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat.
Itakura S; Asari S; Rawson J; Ito T; Todorov I; Liu CP; Sasaki N; Kandeel F; Mullen Y
Am J Transplant; 2007 Feb; 7(2):336-46. PubMed ID: 17283484
[TBL] [Abstract][Full Text] [Related]
35. Immune monitoring of transplant patients in transient mixed chimerism tolerance trials.
Sykes M
Hum Immunol; 2018 May; 79(5):334-342. PubMed ID: 29289741
[TBL] [Abstract][Full Text] [Related]
36. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
37. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
Shimoni A; Nagler A
Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
[TBL] [Abstract][Full Text] [Related]
38. Facilitating cells: role in inducing transplantation tolerance.
Chhabra AY; Ildstad ST
Curr Opin Organ Transplant; 2018 Oct; 23(5):546-551. PubMed ID: 30024415
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
40. Hurdles to the induction of tolerogenic mixed chimerism.
Pilat N; Klaus C; Schwaiger E; Wekerle T
Transplantation; 2009 May; 87(9 Suppl):S79-84. PubMed ID: 19424016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
